Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by Argus

Bristol Myers Squibb (NYSE:BMY) was upgraded by stock analysts at Argus from a “hold” rating to a “buy” rating in a report issued on Wednesday, MarketBeat.com reports. The firm currently has a $75.00 price objective on the biopharmaceutical company’s stock. Argus’ target price indicates a potential upside of 13.92% from the stock’s current price.

BMY has been the subject of a number of other reports. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Bank of America reduced their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research note on Friday. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Finally, Guggenheim reiterated a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday. Ten research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $65.53.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $65.84 on Wednesday. The company has a market cap of $134.49 billion, a P/E ratio of 14.50, a PEG ratio of 0.17 and a beta of 0.22. The firm has a fifty day moving average price of $58.29 and a 200 day moving average price of $58.48. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $68.10.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts predict that Bristol Myers Squibb will post 6.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Norges Bank purchased a new position in Bristol Myers Squibb in the 4th quarter valued at $1,947,272,000. AQR Capital Management LLC lifted its stake in shares of Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after acquiring an additional 16,332,924 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Bristol Myers Squibb by 47.0% in the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after acquiring an additional 7,837,485 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Finally, Man Group plc increased its stake in shares of Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after acquiring an additional 5,503,391 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Reports that AstraZeneca and Bristol Myers Squibb remain in discussions about a potential transaction valued at roughly $400 billion are supporting BMY. A deal could provide shareholders with a premium and create a larger pharmaceutical company with substantial cost-savings potential. The talks remain preliminary and no agreement has been announced. The $400 Billion Reason Bristol-Myers Squibb Stock Is Up Today
• Positive Sentiment: An analyst upgrade has added to buying interest and helped Bristol Myers Squibb set a fresh 12-month high. The move reinforces the view that BMY’s valuation and cash-generating pharmaceutical portfolio remain attractive to investors. Bristol Myers Squibb Sets New 12-Month High on Analyst Upgrade
• Neutral Sentiment: Analysts and financial publications continue to debate whether BMY is undervalued and whether its recent rally can continue. The company’s modest valuation and strong recent earnings performance support the bullish case, but the stock’s advance may also reflect speculative merger enthusiasm rather than a completed transaction. Are Investors Undervaluing Bristol Myers Squibb?
• Negative Sentiment: The AstraZeneca discussions remain uncertain, with no confirmed terms, timetable, or indication that a deal will be completed. Investors should therefore expect volatility if negotiations end or concerns emerge over financing, regulatory approval, or the strategic rationale of a combination. AstraZeneca-BMY Megadeal Talk Sparks Huge Market Rift

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.